Related by context. Frequent words. (Click for all words.) 71 2 methoxyestradiol 68 Panzem R 68 peripherally acting 67 MKC# 67 phenylalanine ammonia lyase 67 topical anti infective 67 Panzem R NCD 67 Currently RegeneRx 66 Factor VIIa 66 Initiates Phase II 66 Interferon alpha 66 PEG PAL PEGylated recombinant 66 TELINTRA 65 gets USFDA nod 65 includes investigational compounds 65 Rebif ® 65 liposomal formulation 65 Recombinant Human 65 inflammatory autoimmune diseases 65 R sorafenib tablets 65 New Chemical Entities 65 TLR9 agonist 65 nitric oxide donating 64 factor VIIa 64 Inhalation Aerosol 64 Locteron ® 64 REGN# 64 Receives Orphan Drug Designation 64 PRT# 64 Nanobody 64 active cellular immunotherapy 64 Inhalation Solution 64 VEGFR2 inhibitor 64 CEQ# 64 generation proteasome inhibitor 64 HepeX B 64 epothilones 63 Shigamabs ® 63 anticancer compounds 63 Lubiprostone 63 AzaSite Plus 63 PEGylation technology 63 Meets Primary Endpoint 63 proteasome inhibitor 63 histone deacetylase HDAC inhibitor 63 topically delivered 63 candidate AP# 63 JAK1 63 cancer immunotherapies 63 Romidepsin 63 anticancer compound 63 MEK inhibitors 63 Pivotal Phase III 63 Prodarsan ® 63 Nexavar ® 63 Onalta 63 transmucosal film 62 Vivecon 62 Excellagen 62 Daclizumab 62 personalized immunotherapy 62 Dapagliflozin 62 GSK# [002] 62 triple VEGF receptor 62 Idera Pharmaceuticals 62 Inc Therapeutic Competitors 62 inhaled formulation 62 Soliris TM eculizumab 62 multi kinase inhibitor 62 Tesetaxel 62 Drug Candidate 62 Phase Ib clinical trials 62 Phase IIb clinical trials 62 FACTIVE R gemifloxacin 62 investigational compounds 62 GVAX R 62 Amrubicin 62 novel antibody therapeutics 62 Shigamabs R 62 PEGylated 62 Entereg R 62 Octreotide 62 Phase 2b clinical trials 61 6R BH4 61 Commences Phase 61 Completes Enrollment 61 PSN# [002] 61 ZFP Therapeutics 61 Ciclesonide 61 non alcoholic steatohepatitis 61 CCR5 antagonist 61 PARI Pharma 61 refractory chronic lymphocytic 61 Trofex 61 Chemokine Therapeutics 61 Peyronie Disease 61 topical gel 61 zileuton 61 candidates bavituximab 61 DAVANAT 61 carcinoid syndrome